Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...

Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

(RTTNews) - Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said ...

Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 ...

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.

Collectively, the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral ...

Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose ...

Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE ...